Press

News


Trellis collaborates with various research organizations and institutions to demonstrate the characteristics and efficacy of its monoclonal antibody candidates. Below is a selection of the company's published research:

October 6, 2017

Trellis Bioscience CellSpot Technology Featured at LakePharma Protein Engineering Symposium

Source Link: https://www.contractpharma.com/contents/view_breaking-news/2017-07-26/cmc-biologics-trellis-bioscience-in-development-and-mfg-pact/

On Friday, October 6, 2017, Lake Pharma hosted its third annual Antibody Engineering Symposium. Trellis Bioscience was in attendance, along with 400 scientists from various biotechnology organizations and institutions, including AbbVie, BMS, Pfizer, Genetech, and UCSF.

July 26, 2017

CMC Biologics, Trellis Bioscience in Development and Mfg. Pact

Source Link: https://www.contractpharma.com/contents/view_breaking-news/2017-07-26/cmc-biologics-trellis-bioscience-in-development-and-mfg-pact/

"CMC ICOS Biologics, Inc., a clinical and commercial manufacturer of monoclonal antibodies and other therapeutic proteins, and Trellis Bioscience LLC, a private, therapeutic antibody company, have entered into a manufacturing agreement for the process development and production of two of Trellis’ monoclonal antibodies (mAbs). Trellis is developing human mAb therapies for bacterial and viral infections, and cancer indications, and has selected CMC Biologics to work with on two of these products. One is for the treatment of respiratory syncytial virus (RSV) infections that aims to provide superior post-infection treatment over the currently marketed mAb by combining antiviral and anti-inflammatory activity. The other is a first-in-class treatment for drug-resistant bacterial infections due to formation of bacterial biofilms, which works by disrupting the biofilm to resensitize bacteria to conventional antibiotics, with activity spanning Gram-positive to Gram-negative bacterial species, including MRSA and Acinetobacter baumanni. CMC Biologics will utilize its CHEF1 Expression System platform. 'We believe that we have chosen an outstanding CDMO to work with,” said Stefan Ryser, Ph.D., chief executive officer of Trellis Bioscience. “In addition, through their use of Multi-column Continuous Chromatography technology, where a reduced quantity of costly chromatography resins is required in the downstream process, CMC Biologics is able to provide Trellis, a significant reduction in our development and manufacturing costs.' "

© 2010-2018 TRELLIS BIOSCIENCE. ALL RIGHTS RESERVED.